Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ:KPRX) announced that CFO Melissa Tosca will present the company's pipeline of therapies for inherited and inflammatory retinal diseases at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

The presentation is scheduled for September 5th, 2025, at 7:00 am EDT. Investors can access the presentation through the company's investor relations website, where it will remain available on-demand for 90 days.

Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27^th Annual Global Investment Conference.

Presentation Details

Date:	Friday, September 5th, 2025
Time:	7:00 am Eastern Daylight Time
Link:	https://ir.kiorapharma.com/news-events/events

 

The replay will be available on-demand for 90 days on Kiora's investor relations website.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contact:
investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265030

FAQ

When is Kiora Pharmaceuticals (KPRX) presenting at the H.C. Wainwright Conference?

Kiora Pharmaceuticals will present on Friday, September 5th, 2025 at 7:00 am Eastern Daylight Time.

Who will present for Kiora Pharmaceuticals at the H.C. Wainwright Conference?

Melissa Tosca, CPA, Chief Financial Officer of Kiora Pharmaceuticals, will present at the conference.

What topics will Kiora Pharmaceuticals (KPRX) cover at the H.C. Wainwright Conference?

The presentation will showcase Kiora's pipeline of therapies targeting inherited and inflammatory retinal diseases.

How can investors access Kiora Pharmaceuticals' H.C. Wainwright Conference presentation?

Investors can access the presentation through Kiora's investor relations website at ir.kiorapharma.com/news-events/events. The replay will be available on-demand for 90 days.